Filtered By:
Procedure: Angioplasty
Countries: Netherlands Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 19 results found since Jan 2013.
Platelet glycoprotein IIb/IIIa inhibitor tirofiban in clopidogrel-na ïve patients undergoing elective percutaneous coronary intervention
CONCLUSION: Ad-hoc PCI in clopidogrel-naïve patients who were treated with high-dose bolus of tirofiban followed by a clopidogrel loading dose immediately after the procedure appeared to be safe.PMID:37713051 | DOI:10.1007/s12471-023-01810-2
Source: Netherlands Heart Journal - September 15, 2023 Category: Cardiology Authors: Zarina Habibi Jasper Luijkx Ben C G Gho Mustafa Ilhan Leo F Veenstra Lex A W Ruiters Mera Stein Arnoud W J van 't Hof Saman Rasoul Source Type: research
The WOEST 2 registry : A prospective registry on antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention
CONCLUSIONS: Patients on combined oral anticoagulation and antiplatelet therapy undergoing PCI are elderly and have both a high bleeding and ischaemic risk. Over time, a NOAC plus clopidogrel became the preferred treatment. The rate of thrombotic and bleeding events was not significantly different between patients on triple or dual therapy or between those on VKAs versus NOACs.PMID:35230636 | DOI:10.1007/s12471-022-01664-0
Source: Netherlands Heart Journal - March 1, 2022 Category: Cardiology Authors: A J W M de Veer N Bennaghmouch W L Bor J P R Herrman M Vrolix M Meuwissen T Vandendriessche T Adriaenssens B de Bruyne M Magro W J M Dewilde J M Ten Berg Source Type: research
Antithrombotic therapy in high-risk patients after percutaneous coronary intervention; study design, cohort profile and incidence of adverse events
CONCLUSION: The high risk for both bleeding and ischaemic events in this cohort of patients with multiple clinical risk factors illustrates the challenges that the cardiologist faces to make a balanced decision on the optimal treatment strategy. This cohort will serve to answer several future research questions about the optimal management of these patients on dual/triple antithrombotic therapy, and the possible value of a wide range of laboratory tests to guide these decisions.PMID:34468944 | DOI:10.1007/s12471-021-01606-2
Source: Netherlands Heart Journal - September 1, 2021 Category: Cardiology Authors: R H Olie P E J van der Meijden M J A Vries L Veenstra A W J van 't Hof J M Ten Berg Y M C Henskens H Ten Cate Source Type: research
Response to: “Arrhythmia paradox in patients with familial hypercholesterolemia”
We read the letter by Mirzaee and Cameron with great interest. We recently assessed the prognostic impact of clinically diagnosed familial hypercholesterolemia (FH) on long-term adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention for chronic and acute coronary syndromes. In our cohort, patients with probable or definite FH according to the Dutch Lipid Clinic Network faced a significant, approximate 2-fold increased risk for subsequent atherothrombotic events (death, myocardial infarction, or stroke) during a 6-year period of follow-up compared with patients with possible or unlikely FH.
Source: Journal of Clinical Lipidology - December 23, 2019 Category: Lipidology Authors: Maximilian Tscharre, Kurt Huber Tags: Letter to Editor Source Type: research
Safety and efficacy of balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension in the Netherlands.
CONCLUSIONS: BPA performed in a CTEPH expert centre is an effective and safe treatment in patients with inoperable CTEPH.
PMID: 31782109 [PubMed - as supplied by publisher]
Source: Netherlands Heart Journal - November 27, 2019 Category: Cardiology Authors: van Thor MCJ, Lely RJ, Braams NJ, Ten Klooster L, Beijk MAM, Heijmen RH, van den Heuvel DAF, Rensing BJWM, Snijder RJ, Vonk Noordegraaf A, Nossent EJ, Meijboom LJ, Symersky P, Mager JJ, Bogaard HJ, Post MC Tags: Neth Heart J Source Type: research
Design and rationale of ischaemia-driven complete revascularisation versus usual care in patients with non-ST-elevation myocardial infarction and multivessel coronary disease: the South Limburg Myocardial Infarction (SLIM) trial.
CONCLUSION: The SLIM trial aims to provide evidence whether FFR-guided complete revascularisation by PCI is superior to usual care with respect to clinical outcomes (major adverse cardiovascular events) in non-STEMI patients with MVD.
PMID: 31531823 [PubMed - as supplied by publisher]
Source: Netherlands Heart Journal - September 16, 2019 Category: Cardiology Authors: Pustjens TFS, Streukens B, Vainer J, Gho B, Ruiters AW, Stein M, Ilhan M, Veenstra L, Theunissen R, Bekkers SCAM, Van't Hof AWJ, Rasoul S Tags: Neth Heart J Source Type: research
Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
In conclusion, the present study identified canagliflozin as a potent inhibitor of human EC proliferation. The anti-proliferative action of canagliflozin is observed in ECs isolated from both the venous and arterial circulation, and is partly due to the blockade of cyclin A expression. In addition, this study found that canagliflozin inhibits tube formation in cultured ECs and mouse aortic rings. Notably, these actions are specific for canagliflozin and not seen with other SGLT2 inhibitors. The ability of canagliflozin to exert these pleiotropic effects on EC function may contribute to both the adverse and salutary actions...
Source: Frontiers in Pharmacology - April 15, 2019 Category: Drugs & Pharmacology Source Type: research
Frailty score for elderly patients is associated with short-term clinical outcomes in patients with ST-segment elevated myocardial infarction treated with primary percutaneous coronary intervention.
CONCLUSIONS: VMS score for frailty is independently associated with short-term mortality and PCI-related SAE in elderly patients with STEMI treated with primary PCI. These results suggest that frailty in elderly patients is an important feature to measure and to be taken into account when developing risk models.
PMID: 30771094 [PubMed - as supplied by publisher]
Source: Netherlands Heart Journal - February 15, 2019 Category: Cardiology Authors: Hermans MPJ, Eindhoven DC, van Winden LAM, de Grooth GJ, Blauw GJ, Muller M, Schalij MJ Tags: Neth Heart J Source Type: research
Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial
Publication date: Available online 25 August 2018Source: The LancetAuthor(s): Marco Valgimigli, Enrico Frigoli, Sergio Leonardi, Pascal Vranckx, Martina Rothenbühler, Matteo Tebaldi, Ferdinando Varbella, Paolo Calabrò, Stefano Garducci, Paolo Rubartelli, Carlo Briguori, Giuseppe Andó, Maurizio Ferrario, Ugo Limbruno, Roberto Garbo, Paolo Sganzerla, Filippo Russo, Marco Nazzaro, Alessandro Lupi, Bernardo CorteseSummaryBackgroundThe Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) programme was designed to assess the comparative safety and effectiveness of ra...
Source: The Lancet - August 25, 2018 Category: General Medicine Source Type: research
